

Godfrey Phillips India

Strong recovery in cigarette volumes in Q1

Despite challenging market conditions, Godfrey Phillips (GP) saw sequential recovery post June. Q1FY22 revenue/EBITDA/PAT grew 49.8%/157%/108.8%, beating our estimates. Cigarette volumes grew 57.4%. International business grew 47% in value terms. With supply chain issues behind, management indicated *Marlboro* supported volume growth. Gross revenue grew 68.2% for tobacco segment; non-tobacco segment including TFS grew 15%. Favorable product mix and higher scale of operations resulted in 482bp gross margin expansion to 54.1%. Despite rising employee cost (+27.3%) and ASP (+55.9%), EBITDA margin expanded 957bp to 23%. Management said July/August saw strong month-on-month recovery. It expects further pick-up in exports and domestic sales, with improving consumer mobility and relaxations post vaccination driving OOH consumption. Our earnings estimates are unchanged. BUY with a DCF-based TP of Rs1,310 (15.1x FY23E EPS).

Cigarette volumes recovered sharply

Cigarette and other related products posted a net sales growth of 49.8%, driven by 57% growth in cigarette volumes; exports grew 47%. Management said that the revival in Q1 was led by (1) recovery to pre-Covid levels in June, (2) gradual increase in consumer mobility in top cities, and (3) faster pace of trade promotions. TFS and chewing tobacco business grew 15%, despite only 93 stores being open; the company expects strong recovery in footfalls in TFS stores in Q2. The management said that consumers opting for contactless shopping through e-commerce led to slower offtake for processed food in Q1.

Higher scale resulted in gross margin expansion; EBITDA margin expanded to 23%

In Q1, GP's gross margin expanded 482bp, led by (1) favorable product mix, (2) lower share of traded goods, and (3) higher operating leverage. Despite rise in ASP (+55.9%), employee cost (+27.3%), and other expenses (+29%), EBITDA margin expanded 957bp to 23%. EBIT margin declined for TFS, as only 93 stores were operational in Q1 and contribution from higher-margin prepared dishes and foods was lower.

Easing lockdowns to improve pace of recovery, as long-term growth drivers are intact

GP's strategy is driven by efforts such as (1) driving cigarette volumes across all key markets, (2) focusing on new markets to catch the shift in demand towards value-for-money cigarettes, (3) reinforcing partnership with Phillip Morris, acting as key growth engine for its distribution efforts, (4) strengthening existing export markets, and (5) capitalizing on fast-growing retail space through TFS, using product innovations. However, increase in competition and surge in discounting to counter illegal imports and local counterfeits remain challenges for the industry. Our discussions with trade partners suggest strong pick-up in value-for-money cigarettes, which bodes well for GP, given its focus on this segment. Also, expected pick-up in footfalls should drive TFS revenues.

Valuation and risks

GP has shown strong recovery in Q1, with supply issues behind, resulting in volume growth. We believe GP could benefit from strong tailwinds for RSFT/DSFT segment and entry into the South with its *Marlboro* brand. Considering the gradual easing of lockdowns post the second Covid wave, we expect rebound in sales. We retain our earnings estimates and maintain BUY with a DCF-based TP of Rs1,310 (15.1x FY23E EPS). Risks to our call include sharp increase in taxation, significant increase in competitive intensity, and disruption in sales due to intermittent lockdowns.

Financial and valuation summary

YE Mar (Rs mn)	1QFY22A	1QFY21A	YoY (%)	4QFY21A	QoQ (%)	FY21A	FY22E	FY23E
Revenues	6,007	4,009	49.8	6,923	(13.2)	24,686	27,055	29,926
EBITDA	1,379	536	157.0	1,489	(7.4)	4,954	5,360	5,978
EBITDA margin (%)	23.0	13.4	957bps	21.5	145bps	20.1	19.8	20.0
Adj. Net profit	1,081	518	108.8	954	13.3	3,569	3,926	4,514
Adj. EPS (Rs)	20.8	10.0	108.8	18.4	13.3	68.6	75.5	86.8
EPS growth (%)						(8.0)	10.0	15.0
PE (x)						15.2	13.9	12.1
EV/EBITDA (x)						8.6	7.2	5.9
PBV (x)						2.3	2.0	1.8
RoE (%)						15.9	15.4	15.8
RoCE (%)						14.7	14.4	14.9

Source: Company, Centrum Broking

Result Update

India I Consumer

16 August, 2021

BUY

Price: Rs1,048

Target Price: Rs1,310

Forecast return: 25%

Market Data

Bloomberg:	GP IN
52 week H/L:	1,110/832
Market cap:	Rs54.5bn
Shares Outstanding:	52.0mn
Free float:	41.4%
Avg. daily vol. 3mth:	1,61,779

Source: Bloomberg

Changes in the report

Rating:	BUY; unchanged
Target price:	Rs1,310; up from Rs1,305
EPS:	FY22E: Rs75.5; unchanged FY23E: Rs86.8; unchanged

Source: Centrum Broking

Shareholding pattern

	Jun-21	Mar-21	Dec-20	Sep-20
Promoter	72.8	72.8	72.6	72.3
FII	10.3	10.6	10.7	10.8
DII	1.7	1.7	1.8	2.4
Public/other	15.3	15.0	15.0	14.6

Source: BSE

Centrum estimates vs Actual results

YE Mar (Rs mn)	Centrum Q1FY20	Actual Q1FY20	Variance (%)
Revenue	5,123	6,007	17.3
EBITDA	871	1,379	58.3
EBITDA margin	17.0	23.0	595bps
PBT	793	1,276	60.8
Adj. PAT	595	1,061	78.4

Source: Bloomberg, Centrum Broking



Shirish Pardeshi

Research Analyst, Consumer
+91-22-4215 9634

shirish.pardeshi@centrum.co.in



Amey Tiwari

Research Associate, Consumer
+91-22-42149771
amey.tiwari@centrum.co.in

Thesis Snapshot

Estimate revision

YE Mar (Rs mn)	FY22E New	FY22E Old	% chg	FY23E New	FY23E Old	% chg
Revenues	27,055	27,055	0.0	29,926	32,385	0.0
EBITDA	5,360	5,360	0.0	5,978	6,469	0.0
EBITDA Margin (%)	19.8	19.8	0bps	20.0	20.0	0bps
PAT	3,926	3,926	0.0	4,514	4,688	0.0
EPS	75.5	75.5	0.0	86.8	86.8	0.0

Source: Centrum Broking

Godfrey Phillips India versus NIFTY 50

	1m	6m	1 year
GP IN	0.4	13.4	11.6
NIFTY 50	4.0	8.2	48.2

Source: Bloomberg, NSE

Key assumptions

Y/E Mar	FY22E	FY23E
Volume Growth (%)	6.5	7.5


Source: Centrum Broking

Valuations


GP has shown strong recovery in Q1, with supply issues behind, resulting in volume growth. We believe GP could benefit from strong tailwinds for RSFT/DSFT segment and entry into the South with its Marlboro brand. Considering the gradual easing of lockdowns post the second Covid wave, we expect rebound in sales. We retain our earnings estimates and maintain BUY with a DCF-based TP of Rs1,310 (15.1x FY23E EPS). Risks to our call include sharp increase in taxation, significant increase in competitive intensity, and disruption in sales due to intermittent lockdowns.

Valuations	Rs/share
DCF-based target price (Rs)	1,310
WACC (%)	13.5
Terminal growth (%)	2.5

P/E mean and standard deviation



EV/EBITDA mean and standard deviation




Source: Bloomberg, Centrum Broking


Peer comparison

Cigarettes	Mkt Cap Rs Bn	CAGR FY21-FY23E (%)			P/E (x)			EV/ EBITDA (x)			RoE (%)		
		Sales	EBITDA	PAT	FY21	FY22E	FY23E	FY21	FY22E	FY23E	FY21	FY22E	FY23E
ITC	2,594.2	10.9	18.4	16.9	19.9	16.3	14.6	15.3	12.2	10.7	21.2	26.4	28.4
Godfrey Phillip	54.4	10.1	9.9	12.5	15.2	13.9	12.1	8.6	7.2	5.9	15.9	15.4	15.8
VST Industries	52.2	9.8	6.9	6.9	16.8	15.8	14.7	10.6	10.1	8.9	34.0	31.2	29.1


Source: Company, Centrum Broking

Exhibit 1: Average monthly volume (mn), quarter-wise


Source: Company Data, Centrum Broking

Exhibit 2: YoY volume growth (%)

Source: Company Data, Centrum Broking

Exhibit 3: Average monthly volume (mn), year-wise

Source: Company Data, Centrum Broking

Exhibit 4: Quarterly revenue and volume growth trends

Source: Company Data, Centrum Broking

Exhibit 5: Segmental performance

Rs mn	Q1FY22	Q1FY21	Growth (%)	FY21	FY20	Growth (%)
Revenue (inc other operating expense)						
Tobacco	6,531	3,883	68.2	26,235	26,771	(2.0)
Less ED	1,240	505	145.4	4,361	1,914	127.8
Net Tobacco revenue	5,290	3,378	56.6	21,874	24,856	(12.0)
Tea and other retail products	777	676	15.0	3,022	3,676	(17.8)
EBIT						
Tobacco	1,278	494	158.9	4,679	5,464	(14.4)
Tea and other retail products	-224	-287	nm	-998	-1,231	nm
EBIT Margin						
Tobacco	24.2	14.6	955 bps	21.4	22.0	-59 bps
Tea and other retail products	-28.9	-42.4	nm	-33.0	-33.5	nm

Source: Company Data, Centrum Broking

Exhibit 6: Quarterly financials – Standalone

(Rs mn)	Q2FY20	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22
Net Sales	7,062	7,440	5,852	4,009	6,877	6,878	6,923	6,007
Cost of goods sold	3,076	3,346	2,472	2,034	3,548	3,363	3,240	2,758
Employee Expenses	709	654	555	525	611	576	643	668
A&SP	373	387	394	86	170	179	233	134
Other Exp	1,541	1,522	1,586	828	1,136	1,243	1,319	1,068
Operating Profit (Core EBITDA)	1,363	1,532	845	536	1,412	1,517	1,489	1,379
Depreciation	348	359	469	335	334	332	384	343
EBIT	1,015	1,173	376	202	1,078	1,185	1,105	1,036
Interest	78	77	73	73	71	70	94	74
Other Income	378	360	359	454	273	408	254	313
Profit Before Tax	1,315	1,456	662	583	1,280	1,524	1,264	1,276
Tax	162	362	179	65	324	382	310	195
Tax rate (%)	12.3	24.8	27.1	11.1	25.3	25.1	24.5	15.3
Adjusted PAT	1,153	1,094	483	518	956	1,142	954	1,081
Growth (%)								
Net Sales	13.2	14.4	(3.4)	(49.4)	(2.6)	(7.6)	18.3	49.8
EBITDA	22.5	44.2	96.6	(72.1)	3.6	(1.0)	76.3	157.0
Adj. PAT	63.8	39.5	36.4	(54.9)	(17.1)	4.3	97.7	108.8
Margin (%)								
Gross Margin	56.4	55.0	57.8	49.3	48.4	51.1	53.2	54.1
EBITDA	19.3	20.6	14.4	13.4	20.5	22.1	21.5	23.0
EBIT	14.4	15.8	6.4	5.0	15.7	17.2	16.0	17.3
PAT	16.3	14.7	8.2	12.9	13.9	16.6	13.8	18.0

Source: Company Data, Centrum Broking

P&L					
YE Mar (Rs mn)	FY19A	FY20A	FY21A	FY22E	FY23E
Revenues	24,494	28,274	24,686	27,055	29,926
Operating Expense	16,106	17,866	15,691	17,299	18,945
Employee cost	2,516	2,500	2,355	2,502	2,831
Others	2,344	2,246	1,687	1,894	2,172
EBITDA	3,528	5,662	4,954	5,360	5,978
Depreciation & Amortisation	959	1,524	1,385	1,585	1,698
EBIT	2,569	4,139	3,569	3,775	4,281
Interest expenses	9	301	307	313	319
Other income	1,066	1,322	1,387	1,787	2,073
PBT	3,626	5,159	4,649	5,248	6,034
Taxes	1,217	1,280	1,080	1,323	1,521
Effective tax rate (%)	33.6	24.8	23.2	25.2	25.2
PAT	2,410	3,879	3,569	3,926	4,514
Minority/Associates	0	0	0	0	0
Recurring PAT	2,410	3,879	3,569	3,926	4,514
Extraordinary items	(18)	(102)	(14)	0	0
Reported PAT	2,391	3,777	3,556	3,926	4,514
Ratios					
YE Mar	FY19A	FY20A	FY21A	FY22E	FY23E
Growth (%)					
Revenue	7.4	15.4	(12.7)	9.6	10.6
EBITDA	55.1	60.5	(12.5)	8.2	11.5
Adj. EPS	71.2	61.0	(8.0)	10.0	15.0
Margins (%)					
Gross	56.3	55.7	50.6	55.0	55.4
EBITDA	14.4	20.0	20.1	19.8	20.0
EBIT	10.5	14.6	14.5	14.0	14.3
Adjusted PAT	9.8	13.7	14.5	14.5	15.1
Returns (%)					
ROE	13.4	19.6	15.9	15.4	15.8
ROCE	13.2	18.9	14.7	14.4	14.9
ROIC	20.8	31.0	21.9	23.4	28.2
Turnover (days)					
Gross block turnover ratio (x)	2.3	1.9	1.6	1.5	1.6
Debtors	12	9	14	14	12
Inventory	184	172	192	193	177
Creditors	79	79	73	77	76
Net working capital	180	177	253	265	287
Solvency (x)					
Net debt-equity	(0.6)	(0.4)	(0.5)	(0.6)	(0.6)
Interest coverage ratio	411.0	18.8	16.1	17.1	18.7
Net debt/EBITDA	(3.2)	(1.5)	(2.4)	(3.0)	(3.2)
Per share (Rs)					
Adjusted EPS	46.3	74.6	68.6	75.5	86.8
BVPS	364.7	396.4	464.8	518.7	583.5
CEPS	64.8	103.9	95.3	106.0	119.5
DPS	10.0	24.0	24.0	31.0	35.0
Dividend payout (%)	21.7	33.0	35.1	41.1	40.3
Valuation (x)					
P/E	22.6	14.0	15.2	13.9	12.1
P/BV	2.9	2.6	2.3	2.0	1.8
EV/EBITDA	12.2	8.1	8.6	7.2	5.9
Dividend yield (%)	1.0	2.3	2.3	3.0	3.3

Source: Company, Centrum Broking

Balance sheet					
YE Mar (Rs mn)	FY19A	FY20A	FY21A	FY22E	FY23E
Equity share capital	104	104	104	104	104
Reserves & surplus	18,859	20,505	24,060	26,865	30,234
Shareholders fund	18,963	20,609	24,164	26,969	30,338
Total debt	412	3,557	3,346	3,346	3,346
Non Current Liabilities	213	245	260	260	260
Def tax liab. (net)	21	24	70	70	70
Total liabilities	19,608	24,435	27,840	30,645	34,014
Gross block	10,431	15,006	15,839	17,686	18,817
Less: acc. Depreciation	(3,782)	(5,187)	(5,852)	(7,437)	(9,135)
Net block	6,649	9,819	9,986	10,249	9,682
Capital WIP	143	165	262	262	262
Net fixed assets	6,793	9,984	10,248	10,510	9,944
Non Current Assets	731	768	501	501	501
Inventories	5,690	6,140	6,706	6,152	6,756
Sundry debtors	670	667	1,237	904	1,000
Cash & Cash Equivalents	11,708	12,267	15,022	19,343	22,592
Loans & advances	13	14	15	15	15
Other current assets	837	1,132	1,455	893	988
Trade payables	2,909	2,506	2,393	2,723	2,832
Other current liab.	3,818	3,882	4,754	4,754	4,754
Provisions	105	151	197	197	197
Net current assets	12,084	13,682	17,091	19,634	23,569
Total assets	19,608	24,435	27,840	30,645	34,014
Cashflow					
YE Mar (Rs mn)	FY19A	FY20A	FY21A	FY22E	FY23E
Profit Before Tax	4,102	6,082	5,328	5,360	5,978
Net Change – WC	690	(1,092)	(1,341)	1,778	(686)
Direct taxes	(1,277)	(1,225)	(991)	(1,323)	(1,521)
Net cash from operations	3,515	3,766	2,996	5,815	3,771
Capital expenditure	(1,238)	(1,150)	(1,267)	(1,117)	(1,131)
Acquisitions, net	(55)	(48)	(242)	0	0
Investments	(1,871)	392	(1,710)	0	0
Others	44	102	38	1,787	2,073
Net cash from investing	(3,119)	(704)	(3,180)	670	942
FCF	396	3,062	(184)	6,485	4,713
Increase/(decrease) in debt	145	(604)	384	(253)	(253)
Dividend paid	(498)	(2,087)	(25)	(1,248)	(1,248)
Interest paid	(41)	(299)	(287)	(313)	(319)
Others	0	0	0	0	0
Net cash from financing	(394)	(2,991)	72	(1,814)	(1,821)
Net change in Cash	2	72	(112)	4,671	2,892

Source: Company, Centrum Broking

Disclaimer

Centrum Broking Limited ("Centrum") is a full-service, Stock Broking Company and a member of The Stock Exchange, Mumbai (BSE) and National Stock Exchange of India Ltd. (NSE). Our holding company, Centrum Capital Ltd, is an investment banker and an underwriter of securities. As a group Centrum has Investment Banking, Advisory and other business relationships with a significant percentage of the companies covered by our Research Group. Our research professionals provide important inputs into the Group's Investment Banking and other business selection processes.

Recipients of this report should assume that our Group is seeking or may seek or will seek Investment Banking, advisory, project finance or other businesses and may receive commission, brokerage, fees or other compensation from the company or companies that are the subject of this material/report. Our Company and Group companies and their officers, directors and employees, including the analysts and others involved in the preparation or issuance of this material and their dependants, may on the date of this report or from, time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. Centrum or its affiliates do not own 1% or more in the equity of this company. Our sales people, dealers, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. We may have earlier issued or may issue in future reports on the companies covered herein with recommendations/information inconsistent or different those made in this report. In reviewing this document, you should be aware that any or all of the foregoing, among other things, may give rise to or potential conflicts of interest. We and our Group may rely on information barriers, such as "Chinese Walls" to control the flow of information contained in one or more areas within us, or other areas, units, groups or affiliates of Centrum. Centrum or its affiliates do not make a market in the security of the company for which this report or any report was written. Further, Centrum or its affiliates did not make a market in the subject company's securities at the time that the research report was published.

This report is for information purposes only and this document/material should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities, and neither this document nor anything contained herein shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. This document does not solicit any action based on the material contained herein. It is for the general information of the clients of Centrum. Though disseminated to clients simultaneously, not all clients may receive this report at the same time. Centrum will not treat recipients as clients by virtue of their receiving this report. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Similarly, this document does not have regard to the specific investment objectives, financial situation/circumstances and the particular needs of any specific person who may receive this document. The securities discussed in this report may not be suitable for all investors. The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries in which the companies mentioned in this report are organized may have restrictions on investments, voting rights or dealings in securities by nationals of other countries. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. Persons who may receive this document should consider and independently evaluate whether it is suitable for his/ her/their particular circumstances and, if necessary, seek professional/financial advice. Any such person shall be responsible for conducting his/her/their own investigation and analysis of the information contained or referred to in this document and of evaluating the merits and risks involved in the securities forming the subject matter of this document.

The projections and forecasts described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. Projections and forecasts are necessarily speculative in nature, and it can be expected that one or more of the estimates on which the projections and forecasts were based will not materialize or will vary significantly from actual results, and such variances will likely increase over time. All projections and forecasts described in this report have been prepared solely by the authors of this report independently of the Company. These projections and forecasts were not prepared with a view toward compliance with published guidelines or generally accepted accounting principles. No independent accountants have expressed an opinion or any other form of assurance on these projections or forecasts. You should not regard the inclusion of the projections and forecasts described herein as a representation or warranty by or on behalf of the Company, Centrum, the authors of this report or any other person that these projections or forecasts or their underlying assumptions will be achieved. For these reasons, you should only consider the projections and forecasts described in this report after carefully evaluating all of the information in this report, including the assumptions underlying such projections and forecasts.

The price and value of the investments referred to in this document/material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. Future returns are not guaranteed and a loss of original capital may occur. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Centrum does not provide tax advice to its clients, and all investors are strongly advised to consult regarding any potential investment. Centrum and its affiliates accept no liabilities for any loss or damage of any kind arising out of the use of this report. Foreign currencies denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies effectively assume currency risk. Certain transactions including those involving futures, options, and other derivatives as well as non-investment-grade securities give rise to substantial risk and are not suitable for all investors. Please ensure that you have read and understood the current risk disclosure documents before entering into any derivative transactions.

This report/document has been prepared by Centrum, based upon information available to the public and sources, believed to be reliable. No representation or warranty, express or implied is made that it is accurate or complete. Centrum has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. The opinions expressed in this document/material are subject to change without notice and have no obligation to tell you when opinions or information in this report change.

This report or recommendations or information contained herein do/does not constitute or purport to constitute investment advice in publicly accessible media and should not be reproduced, transmitted or published by the recipient. The report is for the use and consumption of the recipient only. This publication may not be distributed to the public used by the public media without the express written consent of Centrum. This report or any portion hereof may not be printed, sold or distributed without the written consent of Centrum.

The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Neither Centrum nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

This document does not constitute an offer or invitation to subscribe for or purchase or deal in any securities and neither this document nor anything contained herein shall form the basis of any contract or commitment whatsoever. This document is strictly confidential and is being furnished to you solely for your information, may not be distributed to the press or other media and may not be reproduced or redistributed to any other person. The distribution of this report in other jurisdictions may be restricted by law and persons into whose possession this report comes should inform themselves about, and observe any such restrictions. By accepting this report, you agree to be bound by the foregoing limitations. No representation is made that this report is accurate or complete.

The opinions and projections expressed herein are entirely those of the author and are given as part of the normal research activity of Centrum Broking and are given as of this date and are subject to change without notice. Any opinion estimate or projection herein constitutes a view as of the date of this report and there can be no assurance that future results or events will be consistent with any such opinions, estimate or projection.

This document has not been prepared by or in conjunction with or on behalf of or at the instigation of, or by arrangement with the company or any of its directors or any other person. Information in this document must not be relied upon as having been authorized or approved by the company or its directors or any other person. Any opinions and projections contained herein are entirely those of the authors. None of the company or its directors or any other person accepts any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

Centrum and its affiliates have not managed or co-managed a public offering for the subject company in the preceding twelve months. Centrum and affiliates have not received compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for service in respect of public offerings, corporate finance, debt restructuring, investment banking or other advisory services in a merger/acquisition or some other sort of specific transaction.

As per the declarations given by them, Mr. Shirish Pardeshi and Amey Tiwari, research analyst and and/or any of their family members do not serve as an officer, director or any way connected to the company/companies mentioned in this report. Further, as declared by them, they are not received any compensation from the above companies in the preceding twelve months. They do not hold any shares by them or through their relatives or in case if holds the shares then will not to do any transactions in the said scrip for 30 days from the date of release such report. Our entire research professionals are our employees and are paid a salary. They do not have any other material conflict of interest of the research analyst or member of which the research analyst knows of has reason to know at the time of publication of the research report or at the time of the public appearance.

While we would endeavour to update the information herein on a reasonable basis, Centrum, its associated companies, their directors and employees are under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Centrum from doing so.

Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or Centrum policies, in circumstances where Centrum is acting in an advisory capacity to this company, or any certain other circumstances.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Centrum Broking Limited or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market.

Ratings definitions

Our ratings denote the following 12-month forecast returns:


Buy – The stock is expected to return above 15%.

Add – The stock is expected to return 5-15%.

Reduce – The stock is expected to deliver -5-+5% returns.

Sell – The stock is expected to deliver <-5% returns.

Godfrey Phillips India



Source: Bloomberg

Disclosure of Interest Statement

1 Business activities of Centrum Broking Centrum Broking Limited (hereinafter referred to as "CBL") is a registered member of NSE (Cash, F&O and Currency Derivatives Segments), MCX-SX (Currency Derivatives Segment) and BSE (Cash segment), Depository Participant of CDSL and a SEBI registered Portfolio Manager.

2 Details of Disciplinary History of CBL CBL has not been debarred/ suspended by SEBI or any other regulatory authority from accessing /dealing in securities market.

3 Registration status of CBL: CBL is registered with SEBI as a Research Analyst (SEBI Registration No. INH000001469)

Godfrey Phillips India

4 Whether Research analyst's or relatives' have any financial interest in the subject company and nature of such financial interest No

5 Whether Research analyst or relatives have actual / beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the document. No

6 Whether the research analyst or his relatives has any other material conflict of interest No

7 Whether research analyst has received any compensation from the subject company in the past 12 months and nature of products / services for which such compensation is received No

8 Whether the Research Analyst has received any compensation or any other benefits from the subject company or third party in connection with the research report No

9 Whether Research Analysts has served as an officer, director or employee of the subject company No

10 Whether the Research Analyst has been engaged in market making activity of the subject company. No

11 Whether it or its associates have managed or co-managed public offering of securities for the subject company in the past twelve months; No

12 Whether it or its associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months; No

13 Whether it or its associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months; No

Member (NSE and BSE). Member MSEI (Inactive)**Single SEBI Regn No.: INZ000205331****Depository Participant (DP)**

CDSL DP ID: 120 – 12200

SEBI REGD NO.: CDSL: IN-DP-CDSL-661-2012

PORTFOLIO MANAGER

SEBI REGN NO.: INP000004383

Research Analyst

SEBI Registration No. INH000001469

Mutual Fund Distributor

AMFI REGN No. ARN- 147569

Website: www.centrum.co.in**Investor Grievance Email ID:** investor.grievances@centrum.co.in**Compliance Officer Details:**

Ashok D Kadambi

(022) 4215 9937; Email ID: compliance@centrum.co.in

Centrum Broking Ltd. (CIN :U67120MH1994PLC078125)**Registered Office Address**

Bombay Mutual Building,
2nd Floor, Dr. D. N. Road,
Fort, Mumbai - 400 001

Corporate Office & Correspondence Address

Centrum House
6th Floor, CST Road, Near Vidya Nagari Marg, Kalina, Santacruz (E), Mumbai
400 098.
Tel: (022) 4215 9000 Fax: +91 22 4215 9344